FDA-cleared profile

Neosoma Brain Mets

Neosoma, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.

Clinical role
Semi-automatic tumor contouring and volume-calculation support for treatment planning.
Images and patients
MRI · Brain; previously diagnosed brain metastases
Key limitation
Keep in mind: The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain; previously diagnosed brain metastases Input: T1 post-contrast brain MRI DICOM studies in adults with known or previously diagnosed brain metastases.
  • Who uses it?Intended users: Qualified and trained medical professionals, including radiation-oncology professionals.
  • What does the software produce?Output: GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.
  • What is its most important limitation?Key limitation: The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.

Clinical takeaway. Clinical role: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Semi-automatic tumor contouring and volume-calculation support for treatment planning.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
T1 post-contrast brain MRI DICOM studies in adults with known or previously diagnosed brain metastases.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology and other clinical workflows using external DICOM viewing, editing, or treatment-planning platforms.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified and trained medical professionals, including radiation-oncology professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that the software does not detect tumors for diagnosis, is informational, and does not replace manual contouring. It is limited to previously diagnosed brain metastases and requires professional finalization and modification.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance of Neosoma Brain Mets have been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation testing and a retrospective, blinded, multicenter study of 70 subjects and 70 MRIs evaluating the machine learning model against a reference standard established by three US board certified neuroradiologists. Lesion sensitivity was 0.90 (95% CI 0.87 - 0.94), false positive rate 0.57 lesions per MRI (95% CI 0.35 - 0.80), and DSC 0.86 (95% CI 0.83 - 0.89). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance of Neosoma Brain Mets have been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing." … "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone lesion-level sensitivity for brain metastasis identification on 70 MRIs from 70 subjects: 0.90 (95% CI 0.87 - 0.94).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Neosoma Brain Mets was evaluated in a retrospective, blinded, multicenter study. The testing dataset consisted of 70 subjects and 70 MRIs (one MRI per subject) used for the evaluation of the machine learning model performance." … "Sensitivity rate, to assess the true positive rate of lesion identification". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252922 FDA evidence package for Neosoma Brain Mets

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationBrain; previously diagnosed brain metastases
  • Scopeexact submission
  • Tested versionNeosoma Brain Mets
  • IndependenceSponsor or vendor study

K252922

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K252922 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: T1 post-contrast brain MRI DICOM studies in adults with known or previously diagnosed brain metastases.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252922: Neosoma Brain Mets

  2. Routing

    Source context, not route validation: The FDA package describes DICOM brain MRI input and export or use in external DICOM viewing, editing, and treatment-planning systems.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252922: Neosoma Brain Mets

  3. AI processing

    Source context, not route validation: The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K252922: Neosoma Brain Mets

  4. Returned objects

    Source context, not route validation: GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K252922: Neosoma Brain Mets

  5. Viewer/worklist/report

    Unresolved route: GTV contours and calculated tumor volumes for review, editing, and export to an external clinical platform.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K252922: Neosoma Brain Mets

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM brain MRI input and export or use in external DICOM viewing, editing, and treatment-planning systems.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by qualified and trained medical professionals, including radiation-oncology professionals. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K252922.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K252922.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes an external platform workflow; current hosting, cloud responsibility, security, availability, and local configuration remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes DICOM brain MRI input and export or use in external DICOM viewing, editing, and treatment-planning systems.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K252922.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252922
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain; previously diagnosed brain metastases
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The snapshot contained no PubMed or ClinicalTrials.gov candidates; no evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252922: Neosoma Brain Mets

    U.S. Food and Drug Administration - Published 2025-12-17 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K252922 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09
FDA-cleared K251766

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.

Modality
MRI
Anatomy
Breast
Decision
2025-07-08
FDA-cleared K242825

Prenuvo Body Composition

Prenuvo

Authorized purpose: Prenuvo Body Composition is software that non-invasively quantifies fat, muscle, and organs from compatible MR DICOM datasets and displays internal body information, including liver and body-composition measurements, for adults age 18 and older.

Modality
MRI
Anatomy
Whole-body anatomy, liver, organs, fat, and muscle
Decision
2025-01-17
FDA-cleared K243189

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.

Modality
MRI
Anatomy
Breast, including biopsy-proven breast tumors/findings.
Decision
2024-10-25

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history